



THE *Stockholm Intellectual Property Law Review*

S P E A K E R S

CHALLENGES IN PHARMACEUTICAL NAMING

Carl Wendt, *Groth & Co*

Carl is a senior consultant, specializing in trademarks, domain names and intellectual property strategies. He has experience on strategical advice and handling of international trademark and domain name portfolios from several of Sweden's largest global industrial business. Carl has many years' experience of the special regulations that apply to IP in Life Science, primarily relating to pharmaceuticals and biotechnics in connection with agencies such as the FDA, EMA and Sweden's Medical Products Agency. He has gained his international experience from some of Sweden's major pharmaceutical corporations; Pharmacia & Upjohn and later Pfizer as well as AstraZeneca. In addition, Carl has extensive experience of strategic IP issues within telecom and home electronics through his work with both Ericsson and Electrolux.

Carl is a member of the International Chamber of Commerce's (ICC), reference group for Intellectual Property. At the European Communities Trade Mark Association (ECTA), he is a representative of Sweden, and sits on the Internet Committee.



Kristina Björnerstedt, *Skriptor Zigila*

Kristina is Managing Partner at the international naming agency Skriptor Zigila. Also Kristina is responsible for the Stockholm office, and is Chief Coordinator for the combined offices. She holds a degree in economics from Schartau Business Institute and studied English and Czech, as well as International Relations at Stockholm University. She has also studied French, Italian, Russian and Latin. Kristina began her career at the Embassy of the Czech Republic in Stockholm, and holds a Certificate in Project Management.

She grew up in a bilingual family and speaks fluent Czech. With more than ten years at Skriptor Zigila, she has been working with many international and domestic clients such as Roche, Actavis, Axfood and Bayer.



CRISPR–CAS9 SYSTEM AND GENE EDITING TOOLS

On intellectual property, recent patent disputes and its potential commercial applicability in biotechnology and medicine

Thomas Hedner, *Chalmers University of Technology, Göteborg*

Thomas is Professor of Clinical Pharmacology (MD, PhD, MBA, EconD) from Sahlgrenska Academy at University of Göteborg, Sweden. He has published more than 600 scientific peer-reviewed publications within Medicine and I&E. As a physician, innovator and entrepreneur, he has been involved in several life science start-up companies. He is also holder of several patents within the biotech and medical sector. Currently he is involved in a biomedical start-up at Umeå Biotech Incubator.



BEING EQUITABLE ABOUT EQUIVALENTS UNINTENDED CONSEQUENCES?

John Hornby, *Lambert Hornby IP - UK*

John is an IP Solicitor Advocate with a Natural Sciences degree from the University of Cambridge and is a principal at the London IP boutique firm, Lambert Hornby Limited. John started his career as a barrister in 1984 (Sir Robin Jacob's chambers), spent 20 years at Clifford Chance (14 as a partner) and subsequently operated his own IP consultancy practice. During his career, John has conducted a large number of IP disputes in both the High Court, especially the Patents Court, and the junior IP court (now called the Intellectual Property Enterprise Court), supported and advised in relation to concurrent overseas litigation and played a significant role in many European Patent Office proceedings. Much of his work has been in the life sciences sector in which he has had the conduct of patent trials concerning new chemical entities, formulations and medical devices. John is very experienced in trademark strategy, opposition and litigation, as well as alternative dispute resolution work, including international arbitration. Additionally, John has acted in a substantial number of transactions where IP has been at the centre and drafted many commercial agreements involving IP.



THE SWEDISH DOCTRINE OF EQUIVALENCE: HOW TO REIN IN EQUIVALENCE

Bengt Domeij, Faculty of Law, Uppsala University

Bengt, Professor in private law at Uppsala University, Sweden, is a specialist in patent, trade secrets and licensing law. He has written several books, e.g. *Pharmaceutical Patents in Europe* (2000), *Patentavtal* (2010, *Contracts for Patents*) and *From Employee to Competitor* (2017), together with numerous articles in international journals. Bengt has been on several Swedish government committees studying different patent policy issues. Before joining the Uppsala Law faculty in 2010, Bengt was Professor in intellectual property law at the Royal Institute of Technology in Stockholm.



For more info: INFO@STOCKHOLMIPLAWREVIEW.COM

 **[HTTP://WWW.STOCKHOLMIPLAWREVIEW.COM/](http://WWW.STOCKHOLMIPLAWREVIEW.COM/)**